249 related articles for article (PubMed ID: 36935489)
21. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
22. Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus.
Albert SG; Shrestha E; Ahir V
Endocr Pract; 2024 Mar; 30(3):246-252. PubMed ID: 38097111
[TBL] [Abstract][Full Text] [Related]
23. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.
Masson W; Lavalle-Cobo A; Lobo M; Masson G; Molinero G
Eur J Prev Cardiol; 2021 Mar; 28(1):69-75. PubMed ID: 33606884
[TBL] [Abstract][Full Text] [Related]
24. Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.
Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
Diabetes Obes Metab; 2022 Dec; 24(12):2341-2352. PubMed ID: 35848464
[TBL] [Abstract][Full Text] [Related]
25. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Chang R; Liu SY; Zhao LM
Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
[TBL] [Abstract][Full Text] [Related]
26. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
27. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
28. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
[TBL] [Abstract][Full Text] [Related]
29. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
Singh AK; Singh A; Singh R
Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
[TBL] [Abstract][Full Text] [Related]
31. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
32. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
Giugliano D; Longo M; Scappaticcio L; Bellastella G; Maiorino MI; Esposito K
Cardiovasc Diabetol; 2021 Dec; 20(1):236. PubMed ID: 34915880
[TBL] [Abstract][Full Text] [Related]
33. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
Marilly E; Cottin J; Cabrera N; Cornu C; Boussageon R; Moulin P; Lega JC; Gueyffier F; Cucherat M; Grenet G
Diabetologia; 2022 Dec; 65(12):2000-2010. PubMed ID: 35925319
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
35. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
[TBL] [Abstract][Full Text] [Related]
38. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
39. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
40. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
McGuire DK; D'Alessio D; Nicholls SJ; Nissen SE; Riesmeyer JS; Pavo I; Sethuraman S; Heilmann CR; Kaiser JJ; Weerakkody GJ
Cardiovasc Diabetol; 2022 Aug; 21(1):163. PubMed ID: 36002856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
